



Voltaren advertisement.

[s.l.]: [s.n.], 1988

<https://digital.library.wisc.edu/1711.dl/IUV6GCWKZNCNDN8Q>

<http://rightsstatements.org/vocab/InC/1.0/>

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.

NEW

to the United States




***The number one
prescribed antiarthritic
in the world***

New
Voltaren[®]
diclofenac sodium

25·50·75-MG TABLETS





The number one prescribed antiarthritic in the world

The physician's first choice worldwide:

- ▼ The most frequently prescribed agent of its kind worldwide—over 64 million prescriptions a year¹
- ▼ Documented in over 175 U.S. and international trials in osteoarthritis and rheumatoid arthritis
- ▼ Over 14 years of clinical experience

**Relieves joint pain,
helps restore function
and mobility.**

Please see brief summary of Prescribing Information on last page.

CIBA-GEIGY

New
Voltaren[®]
25·50·75-MG TABLETS
diclofenac sodium



The number one prescribed antiarthritic in the world

Demonstrated effective in U.S. trials:

- ▼ Rapidly relieves joint pain and reduces the inflammation of rheumatoid arthritis and osteoarthritis
- ▼ As effective as ibuprofen in RA, aspirin in OA and RA, indomethacin in ankylosing spondylitis
- ▼ Diffuses into and persists in synovial fluid for extended periods—synovial fluid levels are higher than plasma levels from four to 24 hours after dosing*

**Relieves joint pain,
helps restore function
and mobility.**

Please see brief summary of Prescribing Information on last page.

*It is not known whether diffusion into the joint plays a role in the effectiveness of Voltaren.

CIBA-GEIGY

New
Voltaren[®]
25-50-75-MG TABLETS
diclofenac sodium



The number one prescribed antiarthritic in the world

A record of safety and tolerability*:


- ▼ Safely used by millions of patients the world over for more than 14 years
- ▼ Low incidence of adverse drug reactions confirmed in U.S. trials¹
- ▼ Short plasma half-life (approximately two hours)—no accumulation
- ▼ Can be used in the young or elderly⁺—absorption, metabolism, and excretion not influenced by age²
- ▼ May be prescribed for patients with renal impairment⁺—pharmacokinetics comparable to normal subjects*

**Relieves joint pain,
helps restore function
and mobility.**

*Contraindicated in patients hypersensitive to aspirin, other NSAIDs, or Voltaren. As with other NSAIDs, the most frequent complaints relate to the G.I. tract. In patients treated chronically with NSAID therapy, serious G.I. toxicity such as bleeding, ulceration, and perforation can occur. Elevations of SGOT and/or SGPT, some significant, have been reported in association with Voltaren treatment; as with other NSAIDs, cases of severe hepatic reactions have rarely been reported. Please see brief summary of Prescribing Information on last page.

¹Mean age of the young: 19 years; mean age of the elderly: 68 years.

²Patients with significantly impaired renal function should be under close medical surveillance.



New
Voltaren®
25-50-75-MG TABLETS
diclofenac sodium

**The
number one
prescribed
antiarthritic
in the world**

**For Osteoarthritis, Rheumatoid Arthritis,
and Ankylosing Spondylitis.**

- ▼ The most frequently prescribed antiarthritic in the world—over 64 million prescriptions a year
- ▼ An unsurpassed record of efficacy—safely used by millions of patients the world over for more than 14 years*
- ▼ Small, easy-to-swallow enteric-coated tablets
- ▼ Convenient, flexible dosing

Indication	Recommended Initial Dosage	Recommended Long-term Administration
Osteoarthritis	50 mg b.i.d. or t.i.d. or 75 mg b.i.d.	Titrate based on patient response. Maximum daily dose: 150 mg
Rheumatoid Arthritis	50 mg t.i.d. or q.i.d. or 75 mg b.i.d.	Titrate based on patient response. Maximum daily dose: 200 mg

*Contraindicated in patients hypersensitive to aspirin, other NSAIDs, or Voltaren. As with other NSAIDs, the most frequent complaints relate to the G.I. tract. In patients treated chronically with NSAID therapy, serious G.I. toxicity such as bleeding, ulceration, and perforation can occur. Elevations of SGOT and/or SGPT, some significant, have been reported in association with Voltaren treatment; as with other NSAIDs, cases of severe hepatic reactions have rarely been reported. Please see brief summary of Prescribing Information on last page.